Validation of a prognostic blood-based sphingolipid panel for men with localized prostate cancer followed on active surveillance

• Main Authors: Justin R. Gregg (Author), Lisa Newcomb (Author), Ranran Wu (Author), Jennifer Dennison (Author), John W. Davis (Author), Curtis Pettaway (Author), Louis Pisters (Author), John F. Ward (Author), Brian F. Chapin (Author), Lisly Chéry (Author), Ahmet Urkmez (Author), Andrew M. Fang (Author), Noel Higgason (Author), Patricia Troncoso (Author), Carrie R. Daniel (Author), Christopher Logothetis (Author), Timothy C. Thompson (Author), Andrew W. Hahn (Author), Menghan Liu (Author), Yingye Zheng (Author), Dan W. Lin (Author), Samir Hanash (Author), Ehsan Irajizad (Author), Johannes Fahrmann (Author)
• Format: Book
• Published: BMC, 2024-11-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Background We previously reported that increases in circulating sphingolipids are associated with elevated risk of biopsy Gleason grade group (GG) upgrading in men on Active Surveillance (AS) for prostate cancer. Here, we aimed to validate these findings and establish a blood-based sphingol...